2 High-Quality Health-Care Bargains
Merck and Biogen boast strong pipelines and are in strong positions for long-term growth--and they're undervalued, says Morningstar's Damien Conover.
Merck and Biogen boast strong pipelines and are in strong positions for long-term growth--and they're undervalued, says Morningstar's Damien Conover.
Damien Conover: Here at Morningstar, it's important for us to get our economic moat ratings correct. So, on the health-care team, we've looked back at the last decade and a half to see how our moat ratings have changed. By a factor of 2 to 1, we've increased moats to decreasing moats.
One of the main drivers within the health-care space is pharmaceutical firms and biotechnology firms. Within those firms, innovation really leads to moat expansion. The reason moat expansion is important is if you think about the performance of our 25 cheapest wide- and narrow-moat firms over the last decade and a half, those stocks outperformed the associated index by about 800 basis points. So, when we do upgrade a moat within the health-care space, we tend to increase valuation by about 5%.
Looking forward, a couple of names we think are significantly undervalued and have wide moats are Merck (MRK) and Biogen (BIIB). Both of these firms have very strong pipelines and their patent exposure isn't overly significant. So, not only do we think they are in a good position to have strong returns on invested capital, we think they are in a strong position for long-term growth as well.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.